Evidence map›Paper›PMID 26430458›Full record

ArticleResearch in pharmaceutical sciences

A structural model of the anaphase promoting complex co-activator (Cdh1) and in silico design of inhibitory compounds.

H Rahimi, B Negahdari, M A Shokrgozar, A Madadkar-Sobhani, R Mahdian, A Foroumadi, M Kafshdouzi Amin, M Karimipoor

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Research in pharmaceutical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Isolation, characterization, and expression of theResearch in pharmaceutical sciences · 2025
    Article
  2. Research in pharmaceutical sciences · 2022
    Article
  3. E3 Ubiquitin Ligase APC/CInternational journal of molecular sciences · 2020
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

H RahimiDepartment of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, I.R. Iran.
B NegahdariDepartment of Medical Biotechnology, Advanced Medical Science School, Tehran University of Medical Sciences, Tehran, I.R. Iran.
M A ShokrgozarNational Cell Bank of Iran, Pasteur Institute of Iran, Tehran, I.R. Iran.
A Madadkar-SobhaniLife Sciences Department, Barcelona Supercomputing Center (BSC), Barcelona 08034, Spain ; Department of Bioinformatics, Institute of Biophysics and Biochemistry (IBB), University of Tehran, Tehran, I.R. Iran.
R MahdianDepartment of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, I.R. Iran.
A ForoumadiFaculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, I.R. Iran.
M Kafshdouzi AminFaculty of Paramedical Sciences, Qazvin University of Medical Sciences, Qazvin, I.R. Iran.
M KarimipoorDepartment of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, I.R. Iran.
Pasteur Institute of Iran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaphase promoting complex (APC) controls cell cycle and chromosome segregation. The APC activation occurs after binding of co-activators, cdh1 and cdc20. Cdh1 plays a role in cancer pathogenesis and is known as a potential drug target. The main aim of this study was prediction of 3D structure of cdh1 and designing the inhibitory compounds based on the structural model. First, 3D structure of cdh1 was predicted by means of homology modelling and molecular dynamics tools, MODELLER and Gromacs package, respectively. Then, inhibitory compounds were designed using virtual screening and molecular docking by means AutoDock package. The overall structure of cdh1 is propeller like and each DW40 repeat contains four anti-parallel beta-sheets. Moreover, binding pocket of the inhibitory compounds was determined. The results might be helpful in finding a suitable cdh1 inhibitor for the treatment of cancer.

Indexed as

CancerCdh1Homology modelingVirtual screening and docking

Identifiers

PMID26430458
PMCPMC4578213
OpenAlexW1528351686

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.